Molecular Formula | C206H324N56O65 |
Molar Mass | 4625.11 |
Solubility | H2O: 1mg/mL |
Appearance | solid |
Color | white |
Storage Condition | -20°C |
In vivo study | NEP(1-40) (89 μg/kg, ip, 15 min and 19 h post-injury) administration further shifts distributions of microglia away from an injury-induced activated morphology towards greater proportions of rod and macrophage-like morphologies. Animal Model: 74 male Sprague-Dawley rats (328-377 g). Dosage: 89 μg/kg (97.5% PBS and 2.5% DMSO). Administration: IP, 15 min and 19 h post-injury. Result: Reduced NgR function immediately post-injury. Increased number of amoeboid microglia/macrophages at 2 days post-injury |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. |
WGK Germany | 3 |
biological activity | NEP(1-40) is a peptide antagonist of Nogo-66 receptor (NgR), which reverses the changes in the morphological distribution of microglia caused by damage by inhibiting myelin. |
in vivo study | NEP(1-40) (89 μg/kg, ip, 15 min and 19 h post-injury) administration further shifts distributions of microglia away from an injury-induced activated morphology towards greater proportions of rod and macrophage-like morphologies. Animal Model: 74 male Sprague-Dawley rats (328-377g). Dosage: 89 μg/kg (97.5% PBS and 2.5% DMSO). Administration: IP, 15 min and 19 h post-injury. Result: Reduced NgR function immediately post-injury. Increased number of amoeboid microglia/macrophages at 2 days post-injury |
Animal Model: | 74 male Sprague-Dawley rats (328-377 g). |
Dosage: | 89 μg/kg (97.5% PBS and 2.5% DMSO). |
Administration: | IP, 15 min and 19 h post-injury. |
Result: | Reduced NgR function immediately post-injury. Increased number of amoeboid microglia/macrophages at 2 days post-injury |